{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-120162","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.049816+00:00","generated_at":"2026-06-21T16:20:03.858437+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Armata shareholders elect seven directors, approve executive compensation, ratify EY auditor","bullets":["All seven director nominees elected with between 30.2M and 31.0M votes for each; broker non-votes 858,850.","Non-binding advisory vote on 2021 executive compensation passed: 31,049,313 for, 28,667 against, 14,615 abstain.","Ratification of Ernst & Young as independent auditor for FY2022 passed: 31,938,703 for, 6,798 against, 5,944 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-120162","json":"https://secwatch.observer/filing/0001104659-22-120162.json","markdown":"https://secwatch.observer/filing/0001104659-22-120162.md","text":"https://secwatch.observer/filing/0001104659-22-120162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465922120162/0001104659-22-120162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465922120162/tm2230880d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:20:03.858437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01e050a3b9bbb615e97b6ffae24ac90809828f63","claim":"Armata Pharmaceuticals, Inc. shareholders approved Advisory vote to approve Armata’s 2021 executive compensation at the 2022-11-16 meeting.","evidence_excerpt":"our shareholders next approved on a non-binding advisory basis, Armata’s 2021 executive compensation. The vote for such approval was 31,049,313 shares for, 28,667 shares against, 14,615 shares abstaining, and 858,850 shares of broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922120162/0001104659-22-120162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-16"}],"fact_type":"shareholder_vote"},{"claim_id":"3115cd97621ad12c65de8cace45d8764eeb6fac4","claim":"Armata Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-11-16 meeting.","evidence_excerpt":"our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote for such ratification was 31,938,703 shares for, 6,798 shares against, 5,944 shares abstaining, and 0 shares of broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922120162/0001104659-22-120162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-16"}],"fact_type":"shareholder_vote"},{"claim_id":"e4425428351806e8e14f8394aae800464d662c1a","claim":"Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to the board of directors at the 2022-11-16 meeting.","evidence_excerpt":"the shareholders of Armata Pharmaceuticals, Inc. (“Armata”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2023, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non- Votes Brian Varnum, Ph. D. 30,859,084 233,511 858,850 Jules Haimovitz 30,207,477 885,118 858,850 Odysseas D. Kostas, M.D. 30,227,120 865,475 858,850 Robin C. Kramer 30,968,830 123,765 858,850 Joseph M. Patti, Ph. D. 30,966,995 125,600 858,850 Todd C. Peterson, Ph. D. 30,966,799 125,796 858,850 Sarah Schlesinger, M.D. 30,862,657 229,938 858,850","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922120162/0001104659-22-120162-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}